RxDoctor Payments DataLook up a doctor →

Raymond Tidman, MD

Family Medicine · Blue Ridge, GANPI 1588663686

Payments from drug & device makers

$287,371in general payments, 2019–2025

Across 578 payments — averaging $497.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$196K
  • Pfizer$34K
  • Novo Nordisk AS$19K
  • Sanofi US Services Inc.$14K
  • AstraZeneca$10K
  • Lilly USA, LLC$4K
  • plus $10K from 49 others
$52,196in research payments, 2019–2025

Across 2 payments — averaging $26,098 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Dr.reddy's Laboratories,inc.$52K

What the payments were for

  • Consulting fees$3,75030%
  • Travel & lodging$4133%
  • Food & beverage$8,44767%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)159$195,719
Pfizer35$33,863
Novo Nordisk AS14$19,300
Sanofi US Services Inc.6$13,999
AstraZeneca16$10,472
Lilly USA, LLC22$4,299
Novartis2$2,817
Novo Nordisk49$857
Amgen27$812
Paratek Pharmaceuticals, Inc.13$724
Sanofi-aventis U.S. LLC20$395
Otsuka America Pharmaceutical, Inc.20$349
Antares Pharma, Inc.18$337
GSK11$278
Corcept Therapeutics7$273
Kowa Pharmaceuticals America, Inc.26$228
Esperion Therapeutics, Inc.6$216
Sumitomo Pharma America, Inc.11$203
Eisai Inc.6$193
Astellas Pharma US Inc11$191
Takeda Pharmaceuticals U.S.A., Inc.10$171
Sunovion Pharmaceuticals Inc.7$128
Mylan Specialty L.p.5$125
Biohaven Pharmaceutical Holding Company Ltd.4$121
Johnson & Johnson6$106
Indivior Inc.6$101
Bausch Health US, LLC6$98
Exact Sciences4$87
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$72
Xeris Pharmaceuticals, Inc.4$71
Boehringer Ingelheim3$64
Lundbeck LLC3$61
Bayer3$51
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$51
Teva Pharmaceuticals USA, Inc.3$44
Pulmonx Corporation2$43
Axsome Therapeutics, Inc.2$41
Dexcom, Inc.2$40
Viatris Specialty LLC2$38
Daiichi Sankyo Inc.2$38
Abbott2$38
Idorsia Pharmaceuticals US Inc2$34
Virtus Pharmaceuticals LLC2$28
Masimo Corporation1$20
Biofire Diagnostics, LLC1$20
Phathom Pharmaceuticals, Inc.1$19
Therapeuticsmd, Inc.1$19
Zyla Life Sciences, Inc.1$17
Assertio Therapeutics, Inc.1$17
Biohaven Pharmaceuticals, Inc.1$16
Bristol Myers Squibb1$15
Supernus Pharmaceuticals, Inc.1$14
Arbor Pharmaceuticals, Inc.1$13
Sentynl Therapeutics, Inc.1$12
Biodelivery Sciences International, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$287,371 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$78,210
Medicare patients
239
Services billed
814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide160$174,992
ForteoTeriparatide26$120,683
EliquisApixaban179$117,699
XyostedTestosterone Enanthate104$68,392
FarxigaDapagliflozin Propanediol101$62,078
Repatha SureclickEvolocumab60$44,219
Soliqua 100-33Insulin Glargine/Lixisenatide37$39,765
JardianceEmpagliflozin22$35,263
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl178$28,456
XareltoRivaroxaban45$26,333
MounjaroTirzepatide20$24,965
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$24,706
LinzessLinaclotide36$24,197
JanuviaSitagliptin Phosphate37$21,471
Spiriva HandihalerTiotropium Bromide19$16,075

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$857$174,992160 claims
Lilly USA, LLCForteo, Mounjaro$4,299$145,64846 claims
PfizerEliquis$33,863$117,699179 claims
Antares Pharma, Inc.Xyosted$337$68,392104 claims
AstraZenecaFarxiga$10,472$62,078101 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$395$39,76537 claims
Boehringer IngelheimJardiance$64$35,26322 claims
GSKTrelegy Ellipta, Breo Ellipta$278$30,56054 claims
AbbVieLinzess, Synthroid$195,719$26,53166 claims
Johnson & JohnsonXarelto$106$26,33345 claims
Sumitomo Pharma America, Inc.Gemtesa$203$14,27430 claims
Astellas Pharma US IncMyrbetriq$191$13,61231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Blue Ridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →